|
1000
Asia Pacific J Clin Nutr (1996) 5: 25-28
Asia Pacific J Clin
Nutr (1996) 5: 25-28
Safety
of probiotic bacteria
DC Donohue, S Salminen
Key Centre for Applied and Nutritional Toxicology,
RMIT, Melbourne, Australia
In recent years interest has been renewed in health
promotion and disease prevention by the incorporation of probiotic
bacteria into foods to counteract harmful bacteria in the intestinal
tract. There is considerable interest in extending the range of
foods containing probiotic organisms from dairy foods to infant
formulae, baby foods, fruit juice-based products, cereal-based
products and pharmaceuticals. New and more specific strains of
probiotic bacteria are being sought. Traditional probiotic dairy
strains of lactic acid bacteria have a long history of safe use
and most strains are considered commensal microorganisms with
no pathogenic potential. It cannot be assumed that these novel
probiotic organisms share the historical safety of the traditional
strains. Before their incorporation into products new strains
should be carefully assessed and tested for the safety and efficacy
of their proposed use. As yet, no general guidelines exist for
the safety testing of probiotics. Different aspects of the safety
of probiotic bacteria can be assessed using a panel of in vitro
methods, animal models and human subjects.
Introduction
Probiotic bacteria are commonly defined as viable
bacteria, in single or mixed culture, that have a beneficial effect
on the health of the host.
In the dairy industry the most widely used probiotic
bacteria belong to the group of lactic acid bacteria, though some
bifidobacteria and yeasts are also utilised. The term lactic
acid bacteria (LAB) currently includes the genera Lactobacillus,
Leuconostoc, Pediococcus and Lactococcus. Although some
strains of Streptococcus and Enterococcus share the
properties of LAB, Streptococcus thermophilus is the only strain
currently used in fermented dairy products.
The use of LAB in foods has a long history and most
strains are considered commensal microorganisms with no pathogenic
potential. Their ubiquitous presence in intestinal epithelium and
the human gastrointestinal tract, and their traditional use in fermented
foods and dairy products without significant problems attest to their
safety. Members of the genus Lactobacillus are most commonly
given safe or generally recognised as safe (GRAS) status, whilst members
of the genera Streptococcus and Enterococcus contain
many opportunistic pathogens (Table 1).
The safety of probiotics has been
questioned in recent reviews and clinical 1000 reports which have
drawn attention to cases of human bacteraemia associated with
the presence of LAB1-3.
A variety of strains of probiotic organisms have been used in
the clinical treatment of gastrointestinal disorders in both
children and adults. These include conditions where mucosal
integrity is impaired by antibiotics or radiotherapy, acute
diarrhoea of bacterial or viral origin, and in prevention of
gut colonisation by pathogens4. No evidence of opportunistic
infection by probiotics was seen in these studies.
Recent analyses by Saxelin et al5,6
of clinical isolates of lactobacilli from bacteraemic patients
and comparison with both starter strains and strains used in
pharmaceutical preparations has confirmed that these LAB are
not involved in human infections.
|
Table 1.
Classification of probiotic organisms
and their safety status
Organism |
Infection potential |
Lactobacillus
|
Mainly non-pathogens,
some opportunistic infections (usually in immunocompromised
patients), |
Lactococcus
|
Mainly non-pathogens |
Leuconostoc
|
Mainly non-pathogens,
some isolated cases of infection |
Streptococcus
|
Oral streptococci
mainly non-pathogens (including Streptococcus thermophilus);
some may cause opportunistic infections |
Enterococcus
|
Some strains are
opportunistic pathogens with haemolytic activity and antibiotic
resistance |
Bifidobacterium
|
Mainly non-pathogens,
some isolated cases of human infection |
Saccharomyces
|
Mainly non-pathogens,
some isolated cases of human infection |
|
In addition to these clinical studies and animal studies
showing an absence of infectivity, toxicity studies have also been
carried out7-9 confirming the a 1000 bsence of acute toxicity
of the studied strains of probiotic bacteria. Although acute toxicity
tests were originally designed for chemicals they also give an indication
of any harmful effects associated with extremely high doses of freeze-dried
bacteria.
Studies on
safety of probiotic bacteria
Different aspects of the safety of probiotic bacteria
can be studied using in vitro methods, animal models and human
subjects. As yet no general guidelines exist for the safety testing
of probiotics. However, some recommendations are given in the review
of Donohue et al7 Many countries, including the
European Community, are currently developing more detailed guidelines
with respect to regulations for novel and functional foods and related
probiotic preparations.
In
vitro studies
One of the most important requirements for a probiotic
organism is that it be non-invasive.
In vitro studies are an initial means of assessing
whether a test organism alters the integrity of the intestinal mucosa
and its ability to penetrate the intestinal cells. The local effects
of LAB on the intestine are commonly measured by their in vitro
ability to adhere to human intestinal cell lines and to degrade protective
intestinal mucus. These tests provide an indirect measure of the potential
of LAB to invade intestinal cells and to damage the protective glycoproteins
of the intestinal mucus.
A large number of adhesion studies have been conducted
with different strains of LAB using Caco-2 cells as the most common
cell line. Most strains of LAB have shown no invasive properties in
this test system, even though the selection of new probiotics has
favoured those strains that are strongly adherent to human intestinal
cell lines10,11.
Degradation of intestinal mucus has also been used
as a marker of toxicity. It is thought a stable gastrointestinal microflora
with normal patterns of fermentation and colonisation resistance and
low pH are important in protecting the mucosal layer from injury12.
Strains that do not degrade intestinal mucus or its glycoproteins
are thought to be non-invasive. Strains which do not degrade intestinal
mucosa are also thought to be therapeutic in the probiotic treatment
of mucosal diseases such as pouchitis, ulcerative colitis and Crohns
disease12. In a recent study, commercial probiotic strains
(Lactobacillus GG, Lacto-bacillus acidophilus, Bifidobacterium
bifidum) were shown to be inactive in mucosal degradation12.
In earlier studies, some faecal Bifidobacteria were found to take
part in mucus degradation13,14.
Production of antimicrobial compounds and inhibition
of pathogen growth by LAB has been assessed in vitro.
The competitive exclusion of pathogens altering the balance of the
intestinal microflora has been studied in the Caco-2 cell line. Data
from these tests support the safety of LAB and indicate that many
strains decrease intestinal pH and reduce the numbers of pathogenic
bacteria in the intestinal tract, thus protecting the host10,11.
It has been shown by Australian researchers that LAB strains isolated
from cases of infective endocarditis have some properties in common.
These properties include platelet aggregation, binding of fibronectin
and fibrinogen and the production of glycosidases and proteases which
are postulated as factors in the pathogenesis of endocarditis15,16.
However, comparative studies are needed to determine whether these
are also properties of the strains of LAB normally found in the oral
cavity and the intestinal tract of healthy humans. < 1000 /font>
Animal studies
Acute toxicity studies have been conducted with several
strains of LAB and for reference they have also included Bifidobacterium
longum strains. In general, no acute toxicity has been observed
with any of the tested strains as indicated in Table
2.
Recently, the association of LAB
in germ free rodents has also been used as a criterion for safety.
Ruseler-van Embden et al12 studied the association
or colonisation of germ free rodents with several probiotic lactobacilli
and detected no adverse effects in these animals.
Studies by Goldin and Gorbach17 of the promotion and
induction of colon cancer in laboratory animals have indicated
that adherent lactobacilli appear to delay and slow down the
development of dimethyl hydrazine (DMH)-induced colon tumours.
The strains tested were Lactobacillus acidophilus and
Lactobacillus casei.
Clinical
Studies
A large amount of data from clinical trials
or studies in human volunteers also attest to the safety of
LAB. These studies have included short-term trials in normal
volunteers; prevention and treatment of acute diarrhoea in premature
infants18, infants19,20, children with
diarrhoea20-22, studies on immune effects23
and studies in patients with severe intestinal infections24-26.
A study using Lactobacillus acidophilus preparations
in the effective prevention of intestinal side-effects during
pelvic radiotherapy has also been reported27,28.
Aso et al29 reported that the recurrence-free
interval after resection of superficial bladder cancer in humans
was extended by treatment with Lactobacillus casei Shirota
strain. A summary from the literature of safety studies and
reported effects for probiotic and yoghurt strains is shown
in Table 3.
|
Table 2.
Acute toxicity of probiotic bacteria (Adapted from 7)
Probiotic strain |
LD50
(g/kg body weight)
|
Streptococcus
faecium AD1050a |
>6.6
|
Streptococcus
equinusa |
>6.39
|
La 1000 ctobacillus
fermentum AD002a |
>6.62
|
Lactobacillus
salivarius AD0001a |
>6.47
|
Lactobacillus
GG (ATCC 53103) |
>6.00
|
Lactobacillus
helveticus |
>6.00
|
Lactobacillus
bulgaricus |
>6.00
|
Bifidobacterium
longum |
25
|
a: Heat-treated nonviable preparations
|
All available data indicate that no harmful effects
have been observed in controlled clinical studies with lactobacilli
and bifidobacteria. To the contrary, during treatment of intestinal
infections beneficial effects have been observed including stabilization
of gut mucosal barrier, prevention of diarrhoea and amelioration of
infant and antibiotic-associated diarrhoea.
Table 3. Safety studies and reported effects of current successful probiotic
strains and yoghurt strains.
Probiotic |
Reported effects |
Safety studies
|
strain |
|
In vitro
|
Animal studies
|
Human studies
|
Lactobacillus acidophilus
NCFB 1748 |
Treatment of constipation,
alleviation of radiotherapy related diarrhoea, lowering of faecal
enzymes (4,6,12,27,28,31) |
+
|
+
|
+
|
1000 tr>
Lactobacillus
casei Shirota |
Balancing intestinal
microflora, prevention of intestinal disturbances, treatment of
superficial bladder cancer (4,30,31) |
+
|
+
|
+
|
Lactobacillus
GG (ATCC 53103) |
Treatment of acute viral
and bacterial diarrhoea in infants, prevention of antibiotic associated
diarrhoea, immune enhancing, stabilisation of intestinal permeability
(6,7,10,11,18,20,21,24,26) |
+
|
+
|
+
|
Lactobacillus acidophilus
LA1
|
Immune enhancing, vaccine
adjuvant, balancing intestinal microflora (4,10,23) |
+
|
+
|
+
|
Bifidobacterium bifidum |
Prevention of rotavirus
diarrhoea (4,12,22,31) |
+
|
+
|
+
|
Epidemiological
data
Case reports from the literature of LAB in association
with clinical infection in humans have recently been analysed in reviews
by Gasser2 and Aguirre and Collins1. Both reviews
conclude that, considering their wide-spread consumption, LAB appear
to have very low pathogenic potential. Two recent Finnish studies
confirm that the number of infections associated with LAB is small.
In the first study, genetic methods (16 SRNA) were used to characterise
and identify LAB isolated from blood cultures of bacteraemic patients
in Southern Finland5. The results showed that a newly introduced
probiotic strain in fermented milks was not associated with infections
and the total number of infections caused by lactobacilli was extremely
low. In a further study, lactobacilli isolated from bacteraemic patients
between 1989 and 1994 were compared to common dairy or pharmaceutical
strains6. From a total of 5192 blood cultures 12 were positive
for lactobacilli, an incidence of 0.23 per cent. None of the clinical
cases could be related to lactobacilli strains used by the dairy industry.
In both studies, patients with LAB bacteraemia had other severe underlying
illnesses.
Safety of
n 1000 ovel probiotics
Traditional probiotic dairy strains of LAB have a
long history of safe use. In latter years interest has been renewed
in preventing disease and promoting health by using probiotic bacteria
to fight harmful bacteria in the intestinal tract31. There
is considerable interest in extending the range of foods incorporating
probiotic organisms from dairy foods to infant formulae, baby foods,
fruit juice-based products, cereal-based products and pharma-ceuticals4.
New and more specific strains of probiotic bacteria are being sought.
It cannot be assumed that these novel probiotic organisms share the
historical safety of traditional strains. Before their incorporation
into products new strains should be carefully assessed and tested
for the safety and efficacy of their proposed use. The following suggestions
and recommendations have been proposed as suitable models and methods
to test the safety of probiotic bacteria3,7.
- Determine the intrinsic properties of bacteria
and strains selected for probiotic use eg adhesion factors, antibiotic
resistance, plasmid transfer, enzyme profile.
- Assess the effects of the metabolic products of
the bacteria.
- Assess the acute and subacute toxicity of ingestion
of extremely large amounts of the bacteria.
- Estimate the in vitro infective properties
of probiotic bacteria using cell lines and human intestinal mucus
degradation. Assess infectivity in animal models eg immunocompromised
animals or lethally irradiated animals.
- Determine the efficacy of ingested probiotic bacteria
as measured by dose-response (minimum and maximum dose required,
consequent health effects); assess the effect of massive probiotic
doses on the composition of human intestinal microflora.
- Carefully assess side-effects during human volunteer
studies and clinical studies in various disease-specific states.
- Epidemiological surveillance of people ingesting
large amounts of newly introduced probiotic bacteria for infections.
- The most rigorous safety testing along the above
lines to be undertaken for genetically modified strains and strains
derived from animals.
Chinese abstract
References
- Aguirre M, Collins K. Lactic acid bacteria and
human clinical infection. J Appl Bacteriol 1993; 75: 95-107.
- Gasser F. Safety of lactic acid bacteria and their
occurrence in human clinical infections. Bull Inst Pasteur 1994;
92: 45-67.
- Adams MR, Marteau P. On the safety of lactic acid
bacteria from food. Int J Food Microbiol. 1995; 27: 263-264.
- Lee Y-K, Salminen S. The coming of age of probiotics.
TIFST 1995; 6: 241-245.
- Saxelin M, Rautelin H, Chassy B, Gorbach SL, Salminen
S, Mäkelä P. Lactobacilli and septic infections in Southern Finland
during 1989-1992. Clin Infect Dis 1996 (in press).
- Saxelin M, Rautelin H, Salminen S, Mäkelä P. The
safety of commercial products with viable Lactobacillus strains.
Infectious Diseases in Clinical Practice 1996 (in press).
- Donohue DC, Deighton M, Ahokas JT, Salminen, S.
Toxicity o 1000 f lactic acid bacteria. In: Salminen S, von Wright
A, eds. Lactic acid bacteria. Marcel Dekker Inc, New York 1993:
307-313.
- Ishikara K, Miyakawa H, Hasegawa A, Takazoe I,
Kawai Y. Growth inhibition of Streptococcus mutans by cellular
extracts of human intestinal lactic acid bacteria. Infect Immun
1985; 3: 692-694.
- Momose H, Igarashi M, Era T, Fukuda Y, Yamada M,
Ogasa K. Toxicological studies on Bifidobacterium longum
BB-536. Pharmacometrics 1979; 17: 881-887.
- Coconnier MH, Klaenhammer TR, Kerneis S, Bernet
MF, Servin A. Protein mediated adhesion of Lactobacillus
acidophilus BG2F04 on human enterocyte and mucus secreting
cell lines in culture. Appl Environ Microbiol 1992; 58: 2034-2039.
- Elo S, Saxelin M, Salminen S. Attachment of Lactobacillus
casei strain GG to human colon carcinoma cell line Caco-2: comparison
with other dairy strains. Lett Appl Microbiol 1991; 13: 154-156.
- Ruseler-van Embden JGH, Liesholt LMC, Gosselink
MJ, Marteau P. Inability of Lactobacillus casei strain GG,
L. acidophilus and Bifidobacterium bifidum to degrade
intestinal mucus glycoproteins. Scand J Gastroenterol 1995; 30:
675-680.
- Hoskins LC, Augustines M, McKee WB, Boulding ET,
Kriaris M, Niedermeyer G. Mucin degradation in human colon ecosystems.
Isolation and properties of faecal strains that degrade ABH blood
group antigens and oligosaccharides from mucin glycoproteins. J
Clin Invest 1985; 75: 944-953.
- Coley AM, Lee AJ, Hunter JO. Lactobacillus casei
GG in the treatment of colonic disorders. Microb Ecol Health Dis
1992;5:ii.
- Oakey HJ, Harty DWS, Knox KW. Enzyme production
by lactobacilli and the potential link with infective endocarditis.
J Appl Bacteriol 1995; 78: 142-148.
- Harty DWS, Oakey HJ, Patrikakis M, Hume BBH, Knox
KW. Pathogenic potential of lactobacilli. Int J Food Micr 1994;
24: 179-189.
- Goldin BR, Gorbach SL. Alterations of the intestinal
microflora by diet, oral antibiotics and Lactobacillus: decreased
production of free amines from aromatic nitroso compounds, azo dyes
and glucuronides. J Natl Cancer Inst 1984: 73: 689-695.
- Millar MR, Bacon C, Smith SL, Walker V, Hall MA.
Enteral feeding of premature infants with Lactobacillus GG.
Arch Dis Child 1993; 69: 483-487.
- Sepp E, Mikelsaar M, Salminen S. Effect of administration
of Lactobacillus casei strain GG on the gastrointestinal
microbiota of newborns. Microbial Ecol Health Dis 1993; 6: 309-314.
- Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic
acid bacteria in the treatment of acute rotavirus gastroenteritis.
J Pediatr Gastroenterol Nutr 1995; 20: 333-338.
- Isolauri E, Juntunen M, Rautanen T, Sillanaukee
P, Koivula T. A human Lactobacillus strain (Lactobacillus
casei sp strain GG) promotes recovery from acute diarrhoea in
children. Pediatrics, 1991; 88: 90-97.
- Saavedra JM, Bauman NA, Oung I. Feeding of Bifidobacterium
bifidum and Streptococcus thermophilus to infants in
hospital for prevention of diarrhoea and shedding of rotavirus.
Lancet 1994; 344: 1046-1049.
c1e
- Link-Amster H, Rochat F, Saudan KY, Mignot O, Aeschliman
JM. Modulation of a specific humoral immune response and changes
in intestinal flora mediated through fermented milk intake. FEMS
Immunol Med Microbiol 1994; 10: 55-64.
- Gorbach SL, Chang T, Goldin B. Succesful treatment
of relapsing Clostridium difficile colitis with Lactobacillus
GG. Lancet 1987; 2: 1519.
- Aronsson B, Barany P, Nord CE, Nyström B, Stenvinkel
P. Clostridium difficile-associated diarrhoea in uremic patients.
Eur J Clin Microbiol 1987; 6: 352-356.
- Biller JA, Katz AJ, Flores AF, Buie TM, Gorbach
SL. Treatment of recurrent Clostridium difficile colitis
with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995;
21: 224-226.
- Salminen E, Elomaa I, Minkkinen J, Vapaatalo H,
Salminen S. Preservation of intestinal integrity during radiotherapy
using live Lactobacillus acidophilus cultures. Clin Radiol
1988; 39: 435-437.
- Salminen E, Salminen S, Vapaatalo H. Adverse effects
of pelvic radiotherapy. Progress in Radio-Oncology, Vienna, 1995:501-504.
- Aso Y, Akazan H. Prophylactic effect of a Lactobacillus
casei preparation on the recurrence of superficial bladder cancer.
Urol Int 1992; 49: 125-129.
- Tanaka R, Ohwaki M. A controlled study of the effects
of the ingestion of Lactobacillus casei fermented milk on
the intestinal microflora, its micobiology and immune system of
healthy humans. Proceedings of XII Riken Symposium on Intestinal
Flora, Tokyo, Japan. 1994: 85-104.
- Saavedra JM. Microbes to fight microbes: a not
so novel approach to controlling disease. J Pediatr Gastroenterol
Nutr 1995; 21: 125-129.

Copyright © 1996 [Asia Pacific Journal of Clinical
Nutrition]. All rights reserved.
Revised:
January 19, 1999
.
0
|